131I Iodine

Radiochemicals

Iodine-131

Request a Quote Ask a specialist

Availability
Weekly
Half life
8.02 days
Radiochemical purity
>97.0%
Concentration
> 160.2 GBq/ml
Regions
Asia · Canada · Latin America · Middle East · USA

I-131 major uses include the treatment of thyrotoxicosis (hyperthyroidism) and some types of thyroid cancer that absorb Iodine. I-131 is thus used as direct radioisotope therapy to treat hyperthyroidism caused by Graves’ disease, as well as in hyperactive thyroid nodules. It is also employed as a radioactive label for certain therapeutic radiopharmaceuticals, such as I-131-metaiodobenzylguanidine (I-131-MIBG), used for imaging and treatment of pheochromocytoma and neuroblastoma. In these therapeutic applications, I-131 destroys tissues by emitting short-range beta radiation. Beta radiation is responsible for about 90% of the tissue damage; the isotope’s gamma radiation responds for the remaining destruction. In therapeutic applications, I-131 can also be visualized in diagnostic scans, due to detection of its emitted gamma radiation.

Weekly supply windows

Calibrated to your delivery date, shipped from qualified reactor and cGMP partners.

Regulatory support

DMF assistance and documentation for Canada, USA and Latin America filings.

Cold-chain logistics

Type A packaging, licensing and customs handled by our regional order desks.

Thinking… Something went wrong. Please try again.